aflibercep

Aflibercept is a fully humanized recombinant fusion protein that acts as a decoy VEGF receptor and a “trap,” exhibiting binding affinity for VEGF-A, VEGF-B, and PIGF (placental growth factor). By blocking the binding of these ligands to endogenous VEGF receptors, it inhibits pathological angiogenesis and is used in both ophthalmology and oncology.

Aflibercept is a recombinant fusion protein antibody composed of the Ig domains of VEGFR1 and VEGFR2 and the Fc domain of human IgG1. Aflibercept inhibits VEGF signaling and is a commonly used tool in biological research for suppressing pathological angiogenesis.